Ísrael - enska - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 1500 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Ísrael - enska - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 250 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Ísrael - enska - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 3000 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Suður-Afríka - enska - South African Health Products Regulatory Authority (SAHPRA)

novo nordisk (pty) ltd û (rivonia) - tablet - see ingredients - each tablet contains norethisterone acetate a oestradiol hemihydrate a

Evrópusambandið - enska - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa - hemophilia a - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). novoeight can be used for all age groups.

Bandaríkin - enska - NLM (National Library of Medicine)

novo nordisk - coagulation factor viia recombinant human (unii: ac71r787ov) (coagulation factor viia recombinant human - unii:ac71r787ov) - coagulation factor viia recombinant human 1 mg in 1 ml - novoseven rt, coagulation factor viia (recombinant), is indicated for: none known. risk summary there are no adequate and well-controlled studies using novoseven rt in pregnant women to determine whether there is a drug-associated risk. treatment of rats and rabbits with novoseven in reproduction studies has been associated with mortality at doses up to 6 mg per kg body weight and 5 mg per kg body weight respectively. at 6 mg per kg body weight in rats, the abortion rate was 0 out of 25 litters; in rabbits at 5 mg per kg body weight, the abortion rate was 2 out of 25 litters. twenty-three out of 25 female rats given 6 mg per kg body weight of novoseven gave birth successfully, however, two of the 23 litters died during the early period of lactation. no evidence of teratogenicity was observed after dosing with novoseven. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - insulin aspart; insulin aspart protamine - suspension for injection - 30unit/1ml ; 70unit/1ml

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

novo nordisk ltd - insulin aspart; insulin aspart protamine - suspension for injection - 30unit/1ml ; 70unit/1ml

Singapúr - enska - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - general hospital - novofine® plus needles having a thread interface are intended for use with needle-based pen injectors for the subcutaneous injection of drugs, including insulin, glp-1 and growth hormone products. the intended users of the novofine® plus needle include patients with diabetes mellitus or various types of growth hormone deficiencies as well as healthcare professionals (hcp’s).

Suður-Afríka - enska - South African Health Products Regulatory Authority (SAHPRA)

novo nordisk (pty) ltd û (rivonia) - tablet - see ingredients - each tablet contains repaglinide 0,5 mg